Article Text

PDF

Coronary heart disease
Protective effect of Lipo-PGE1 on myocardial injury following elective percutaneous coronary intervention in patients with angina pectoris
  1. Luochufan
  1. First Affiliated Hospital of Zhongshan Medical University, Guangzhou, China

Abstract

Objectives This pilot study is a prospective, single-centre, randomised and open-label trial undertaken to investigate potential protective effects of lipo-PGE1 in patients undergoing elective PCI for AP.

Methods A total of 79 patients with stable or unstable AP who had been referred for elective PCI were enrolled and randomly assigned to two groups. Patients in the control group (n=39) received only the conventional medications and those in the PGE1 group (n=40) received additional 20 µg/day of lipo-PGE1 intravenously, starting at least 48 h before PCI and continuing for 5 days.

Results The incidence of post-procedural elevation of cTnT above the upper limit of normal was 25.0% in the PGE1 group and 51.3% in the control group (p=0.016), and the incidence of CK-MB elevation above the upper limit of normal was significantly lower in the PGE1 group (12.5% vs 30.8%, p=0.048). Postprocedural cTnT concentration (ng/ml) was significantly higher in the control group than in the PGE1 group at each time after PCI. Postprocedural CK-MB level (ng/ml) was also significantly higher in the control group at each time. Lipo-PGE1 was well tolerated and there were no instances of serious adverse events or side effects.

Conclusions Lipo-PGE1 treatment appears to reduce postprocedural myocardial injury following elective PCI for angina patients.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.